5 Thought-Provoking Analyst Inquiries From Inspire Medical Systems’s Fourth Quarter Earnings Call
Inspire Medical Systems reported strong Q4 performance with revenue growth and improved operating margins, but investor sentiment was cautious due to uncertainty around reimbursement for the Inspire 5 system. Analysts focused their inquiries on securing clarity for new coding reimbursements, managing potential fee reductions, and addressing patient demand amid provider bottlenecks. The company's management outlined strategies to navigate these challenges, including ongoing negotiations with payers and focusing on less affected centers.
Navigating the Shift: How New Billing Codes Will Shape Inspire Medical’s Trajectory
Inspire Medical Systems is preparing for significant operational changes in Q1 2026, driven by new CPT codes for its neurostimulation system and a planned declassification of its board of directors. The company's focus will be on ensuring clear reimbursement guidelines, expanding therapy availability, and advancing its pipeline with the upcoming Inspire VI system, all while navigating these shifts to sustain growth. Investors will closely watch upcoming financial results and management commentary regarding these changes.
Inspire Medical Systems Clarifies Coding for Inspire V
Inspire Medical Systems has clarified that its Inspire V procedure will now be billed under CPT code 64582 with a -52 modifier, following recent reimbursement policy updates. This change is expected to reduce professional fees by 10% to 50% and may impact physician willingness to perform the procedure, leading the company to revise its 2026 revenue outlook to $950 million to $1.0 billion. Inspire is pursuing a long-term solution by working towards the creation of a separate CPT code for the Inspire V procedure.
5 Insightful Analyst Questions From Inspire Medical Systems's Q4 Earnings Call
Inspire Medical Systems' (INSP) Q4 performance saw strong revenue growth and improved operating margins, beating analyst estimates, although market response was negative due to uncertainty surrounding reimbursement for its Inspire 5 system. Management highlighted strong patient demand and successful rollout of Inspire 5, but impending changes in procedure coding and professional fee reductions raised investor caution. Analyst questions focused on reimbursement clarity, impact of coding changes, achieving guidance amidst fee cuts, pathway to new CPT codes, and managing demand with potential physician deterrence.
Inspire Medical Systems, Inc. (NYSE:INSP) Given Consensus Recommendation of "Hold" by Brokerages
Inspire Medical Systems (NYSE:INSP) has received a consensus "Hold" rating from 19 analysts, with an average one-year price target of $108.94. The company recently reported strong quarterly earnings, beating estimates with EPS of $1.65 and revenue of $269.1 million, a 12.2% year-over-year increase. Despite the positive earnings, several firms have trimmed their price targets, and the stock is currently trading significantly below its 50 and 200-day moving averages and its 12-month high.
A Look At Inspire Medical Systems (INSP) Valuation After Guidance Cut And Reimbursement Uncertainty
Inspire Medical Systems (INSP) faces valuation questions after cutting its 2026 guidance and highlighting reimbursement uncertainty, leading to a significant stock price decline. Despite analysts pegging its fair value much higher, investors are reassessing growth and risk amidst factors like slower rollout and legal scrutiny. The article suggests investors examine the numbers and potential risks themselves to determine if the company is undervalued or if its current price reflects future growth challenges.
Aberdeen Group plc Raises Stock Holdings in Inspire Medical Systems, Inc. $INSP
Aberdeen Group plc significantly increased its stake in Inspire Medical Systems (NYSE:INSP) by 63.0% in Q3, now owning 396,340 shares valued at approximately $29.97 million. This move comes as Inspire Medical Systems reported strong Q4 results, surpassing analyst expectations with an EPS of $1.65 and revenue of $269.1 million. Despite a consensus "Hold" rating from analysts with an average price target of $108.94, institutional investors are actively adjusting their positions in the medical technology company.
M&G PLC Increases Position in Inspire Medical Systems, Inc. $INSP
M&G PLC significantly increased its stake in Inspire Medical Systems, Inc. (NYSE:INSP) by 173.9% in the third quarter, now owning 144,960 shares valued at $10.7 million. Several other institutional investors also adjusted their positions in the company. Despite varied analyst ratings, Inspire Medical Systems currently holds a "Hold" consensus rating with an average price target of $108.94.
Short Interest in Inspire Medical Systems, Inc. (NYSE:INSP) Increases By 31.1%
Inspire Medical Systems (NYSE:INSP) experienced a significant 31.1% increase in its short interest during January, reaching 3,868,836 shares by January 30th. This represents 13.6% of the company's shares sold short, with a short-interest ratio of 2.6 days. Despite beating Q4 earnings estimates, the company's stock faced downgrades and a share price decline due to lower-than-expected 2026 revenue guidance and concerns about coding and reimbursement headwinds.
Results: Inspire Medical Systems, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Inspire Medical Systems, Inc. (NYSE:INSP) recently reported full-year results, exceeding expectations with a significant profit surprise despite a 9.0% share price drop. While analysts have lowered revenue forecasts for 2026, they have become more optimistic about the company's earnings per share. However, the price target has been cut by 33% to US$82.86, reflecting concerns over declining revenue growth compared to historical performance and industry averages.
Results: Inspire Medical Systems, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Inspire Medical Systems, Inc. (NYSE:INSP) recently reported full-year results, exceeding profit expectations despite analysts anticipating lower revenues. Following these results, analysts have updated their forecasts, decreasing the revenue outlook while becoming more bullish on the company's earnings power. Consequently, price targets have been cut, and the long-term revenue growth is expected to slow significantly compared to historical rates and the broader industry.
Results: Inspire Medical Systems, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Inspire Medical Systems (NYSE: INSP) exceeded profit expectations in its full-year results, with statutory profit per share 401% above forecasts, despite revenues meeting analyst predictions. Analysts have since lowered revenue forecasts for 2026 but increased their earnings per share estimates, leading to a 33% cut in the consensus price target to US$82.86. The company's projected revenue growth of 6.0% for 2026 is significantly slower than its historical 34% over the last five years and falls below the 7.7% growth anticipated for the wider industry.
Thrivent Financial for Lutherans Has $1.44 Million Stake in Inspire Medical Systems, Inc. $INSP
Thrivent Financial for Lutherans significantly reduced its holdings in Inspire Medical Systems, Inc. by 82.5% in the third quarter, now holding 19,415 shares valued at $1.44 million. This move comes as Inspire Medical Systems reported strong Q4 earnings, beating estimates, but issued a cautious 2026 revenue outlook and flagged potential coding and reimbursement headwinds, leading to analyst downgrades and a share price decline. Other institutional investors showed mixed activity, with some increasing and others decreasing their stakes.
Inspire Medical Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Inspire Medical Systems, Inc. - INSP
Kahn Swick & Foti, LLC (KSF) has launched an investigation into the officers and directors of Inspire Medical Systems, Inc. (INSP) following allegations that the company failed to disclose material information regarding the launch of its Inspire V device. The investigation stems from a significant cut in 2025 earnings guidance after previously undisclosed issues led to an "elongated timeframe" for the device's rollout. A securities class action lawsuit is currently ongoing against the company and some executives.
Inspire Medical Systems, Inc. SEC 10-K Report
Inspire Medical Systems, Inc. has released its 2025 10-K report, detailing significant financial growth with revenues of $911.981 million and a net income of $145.422 million, largely due to increased market penetration and a deferred tax benefit. The company expanded its presence, launched the Inspire V neurostimulator, and has strategic plans for international growth and R&D investment. However, Inspire faces challenges including heavy reliance on its single product, market fluctuations, competition, and ongoing regulatory and reimbursement risks.
Analysts Offer Insights on Healthcare Companies: Doximity (DOCS), Atricure (ATRC) and Inspire Medical Systems (INSP)
Three analysts recently provided bullish sentiments on healthcare companies Doximity (DOCS), Atricure (ATRC), and Inspire Medical Systems (INSP). Bank of America Securities maintained a Buy rating on Doximity with a $56 price target, Canaccord Genuity maintained a Buy on Atricure with a $64 price target, and Piper Sandler maintained a Buy rating on Inspire Medical Systems with an $85 price target. All three stocks show significant upside based on analyst consensus price targets.
Inspire Medical Systems (NYSE:INSP) Lowered to "Hold" Rating by Wells Fargo & Company
Wells Fargo & Company downgraded Inspire Medical Systems (NYSE:INSP) from a "strong-buy" to a "hold" rating following the company's Q4 earnings beat but reduced FY2026 revenue guidance. The downgrade reflects concerns over a potential coding change that could pressure physician reimbursement and procedure volumes, leading to a sharp share selloff and multiple analyst price target reductions. The stock now holds an average "Hold" rating with an average target price of $110.65 from analysts.
Inspire Medical Systems (INSP) Q4 Margin Surge To 15.9% Tests Cautious Earnings Narratives
Inspire Medical Systems (INSP) reported strong Q4 2025 results with a 15.9% net margin, significantly higher than analyst expectations and the previous year. While this supports bullish narratives for growth, a wide swing in quarterly performance and cautious analyst forecasts for a slight earnings decline over the next three years present concerns for skeptics. Investors are evaluating whether the current high margins are sustainable and if the company's valuation gap indicates opportunity or risk given its volatile performance.
Inspire Medical Systems (NYSE:INSP) Price Target Cut to $66.00 by Analysts at Jefferies Financial Group
Jefferies Financial Group has decreased its price target for Inspire Medical Systems (NYSE:INSP) from $81.00 to $66.00, while maintaining a "hold" rating due to narrowed 2026 revenue guidance and concerns over coding and reimbursement uncertainties. Despite beating Q4 revenue and EPS estimates, the company's shares experienced a significant sell-off, and short interest increased, leading to a consensus "Hold" rating from analysts with an average price target of $110.65. The revised outlook is primarily driven by potential impacts on procedure volumes and physician fees from coding clarifications.
Inspire Medical Systems (INSP) Stock Trades Down, Here Is Why
Inspire Medical Systems' shares dropped 8.7% after the company provided weak full-year revenue guidance, which overshadowed strong fourth-quarter earnings. The lowered outlook is attributed to uncertainty surrounding new medical billing code clarifications for its Inspire V procedure, potentially reducing physician reimbursement. This news follows a previous drop related to similar concerns over billing codes for its main therapy, contributing to a 35% decline in the stock since the beginning of the year.
Inspire Medical Systems stock hits 52-week low at $56.17
Inspire Medical Systems Inc. (INSP) stock has fallen to a new 52-week low of $56.17, reflecting a significant 63.55% decline over the past year. Despite strong fundamentals and a "GREAT" financial health score, the company faces headwinds due to reimbursement issues, leading to lowered price targets and downgrades from multiple analysts. InvestingPro suggests the stock might be undervalued despite its recent performance.
This Inspire Medical Systems Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday
This article details four significant analyst downgrades for Thursday. Baird downgraded Inspire Medical Systems (INSP) from Outperform to Neutral, citing a reduced price target. Additionally, JP Morgan lowered Valvoline Inc (VVV) to Underweight, while Wells Fargo downgraded both Arcus Biosciences Inc (RCUS) and Rollins Inc (ROL) to Equal-Weight, adjusting their price targets accordingly.
Inspire Medical Systems, Inc. (NYSE:INSP) Q4 2025 earnings call transcript
This document is an earnings call transcript for Inspire Medical Systems, Inc. (NYSE:INSP) for its Q4 2025 financial results. It contains detailed discussions regarding the company's performance and future outlook as presented during the call.
Inspire Medical Systems, Inc. (NYSE:INSP) Q4 2025 Earnings Call Transcript
Inspire Medical Systems, Inc. reported strong Q4 2025 earnings, beating expectations with an EPS of $1.65. The company's Q4 revenue increased by 12% to $269 million, and full-year revenue grew by 14% to $912 million. A major focus of the call was the ongoing reimbursement challenges for their Inspire 5 system, specifically the coding changes and the potential reduction in physician fees, leading to a revised 2026 revenue outlook of $950 million to $1,000 million.
Inspire Medical Systems (INSP) Stock Trades Down, Here Is Why
Inspire Medical Systems (INSP) shares fell 8.7% after the company's weak full-year revenue guidance offset strong Q4 earnings. The guidance miss is attributed to uncertainty surrounding new medical billing code clarifications for its Inspire V procedure, which could reduce physician reimbursement. Despite beating Q4 revenue and profit estimates, investors focused on the cautious outlook, causing the stock to drop significantly.
How Investors May Respond To Inspire Medical Systems (INSP) Surging 2025 Profit Versus Cautious Expectations
Inspire Medical Systems (INSP) reported strong full-year 2025 results, with net income rising to US$145.42 million and EPS reaching US$4.95, significantly outperforming previous analyst caution. This sharp improvement in profitability, despite earlier tempered expectations, highlights the company's ability to convert revenue growth into bottom-line gains. Investors will be evaluating how this performance reshapes the investment narrative, particularly concerning future guidance, execution risks, and evolving reimbursement trends for its sleep apnea therapy.
Inspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results
Inspire Medical Systems announced strong financial results for the fourth quarter and full year 2025, driven by a 12% increase in Q4 revenue and 14% for the full year. The company successfully launched its Inspire V system and received FDA approval for 3.0T MRI compatibility. Despite challenges with reimbursement coding for the new system, Inspire has provided a 2026 revenue outlook ranging from $950 million to $1.0 billion, expecting 4% to 10% annual growth.
Inspire Medical Systems Q4 Earnings Call Highlights
Inspire Medical Systems discussed its Q4 and full-year 2025 earnings, focusing on coding and reimbursement challenges for its Inspire 5 system, which led to a widened 2026 revenue outlook. The company reported solid revenue growth and operational progress, emphasizing efforts to work with payers on reimbursement while advancing R&D for future systems. Despite near-term uncertainties, Inspire is pursuing a new CPT code for long-term stability and has secured FDA approval for 3T MRI compatibility.
Earnings call transcript: Inspire Medical Systems Q4 2025 Earnings Beat Forecasts
Inspire Medical Systems (INSP) reported Q4 2025 earnings and revenue that significantly beat forecasts, with EPS of $1.65 (vs. $0.68 expected) and revenue of $269.1 million (vs. $263.81 million expected). The company launched its Inspire 5 system and received FDA approval for 3 Tesla MRI compatibility, driving strong performance, but faces challenges with CPT coding changes affecting physician reimbursement. For 2026, Inspire provided revenue guidance of $950 million to $1 billion and expects continued growth despite potential regulatory hurdles.
Inspire Medical Systems (NYSE:INSP) Stock Plunges on Weak 2026 Outlook Despite Q4 Earnings Beat
Inspire Medical Systems (NYSE:INSP) stock plunged over 6% in after-hours trading despite beating Q4 earnings estimates, due to a conservative 2026 revenue outlook that fell below analyst consensus. While Q4 revenue narrowly missed expectations, EPS significantly exceeded forecasts, indicating strong operational efficiency. The primary concern for investors is the company's midpoint sales forecast of $975 million for 2026, which is 2.7% lower than the $1.025 billion analyst consensus, overshadowing recent operational milestones like the Inspire V launch and FDA approval for 3.0T MRI compatibility.
Inspire: Q4 Earnings Snapshot
Inspire Medical Systems Inc. reported strong fourth-quarter results, with net income reaching $136.1 million, or $4.66 per share. Adjusted earnings of $1.65 per share surpassed analyst expectations of 69 cents, and revenue of $269.1 million also exceeded forecasts. For the full year, the company posted a profit of $145.4 million on $912 million in revenue, and it provided a positive outlook for full-year earnings and revenue.
Inspire Medical Systems (NYSE:INSP) Posts Better-Than-Expected Sales In Q4 CY2025 But Stock Drops
Inspire Medical Systems (NYSE:INSP) exceeded Q4 CY2025 revenue and adjusted EPS expectations, with sales up 12.2% year-on-year to $269.1 million and adjusted EPS of $1.65. Despite the strong quarterly performance and raised full-year EPS guidance, the stock dropped 6.3% due to concerns over coding clarification for its Inspire V procedure, which may reduce physician reimbursement and impact future adoption.
Inspire Medical Systems: Q4 Earnings Insights
Inspire Medical Systems (NYSE: INSP) reported its Q4 earnings on February 11, 2026, beating estimated earnings per share (EPS) by 139.13% with an EPS of $1.65 against an estimate of $0.69. Revenue increased by $29.36 million year-over-year. The company's stock previously saw a 15.33% increase after beating EPS estimates in the prior quarter.
Inspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results
Inspire Medical Systems, Inc. announced strong financial results for Q4 and full year 2025, driven by the successful launch of its Inspire V system and FDA approval for 3.0T MRI compatibility. Despite challenges with reimbursement coding for Inspire V, the company posted significant revenue growth and profitability. Inspire provided a revised 2026 outlook, anticipating continued growth while addressing coding uncertainties in the first quarter.
Preview: Inspire Medical Systems's Earnings
Inspire Medical Systems (NYSE: INSP) is slated to release its quarterly earnings report on Wednesday, 2026-02-11, with analysts expecting an EPS of $0.69. The company has a strong financial standing, leading peers in revenue growth and gross profit, though it ranks lower in Return on Equity. Despite a 62.72% share price decline over the last 52 weeks, analysts have an Outperform consensus rating with a potential 112.57% upside.
Inspire Medical Systems stock jumps ahead of earnings — what investors are watching next
Inspire Medical Systems (NASDAQ:INSP) saw its stock jump 6% ahead of its fourth-quarter and full-year earnings report. Investors are keenly awaiting the company's 2026 outlook and details on implant volume cadence, profitability, and operating costs, especially following preliminary unaudited revenue numbers released last month. The stock's performance on Tuesday was driven by anticipation, not new headlines, as traders positioned themselves before the official results are released.
Inspire Medical Systems (INSP) Q4 Results: Anticipated Outcomes
Inspire Medical Systems (INSP) is set to announce its Q4 financial results, with analysts projecting $266.3 million in revenue and $0.68 adjusted EPS. The company has a history of outperforming revenue expectations but has seen a significant stock decline recently amid broader market volatility. The article provides context by reviewing the performance of industry peers and discusses the current economic climate affecting the healthcare equipment sector.
Inspire Medical Systems (INSP) Q4 Earnings: What To Expect
Inspire Medical Systems (INSP) is set to report its Q4 earnings, with analysts expecting an 11.1% year-on-year revenue increase to $266.3 million and adjusted earnings of $0.68 per share. The company has a strong history of exceeding revenue estimates, although its stock has underperformed recently, down 31.7% over the last month. While the healthcare equipment and supplies sector has seen mixed results, analysts have largely reconfirmed their estimates for INSP.
Inspire Medical Systems, Inc. $INSP Shares Sold by New York State Common Retirement Fund
New York State Common Retirement Fund significantly reduced its stake in Inspire Medical Systems (NYSE:INSP) by 73.7% in Q3, selling over 141,000 shares. Another insider, Director Shawn McCormick, also sold 2,000 shares in November, decreasing his position by over 7%. Despite institutional ownership at nearly 95%, analysts maintain a "Hold" rating for the stock, with a consensus target price of $133.47.
A Look At Inspire Medical Systems (INSP) Valuation After Recent Share Price Weakness
Inspire Medical Systems (INSP) has experienced recent share price weakness despite a high fair value estimate of $124.40, suggesting it may be undervalued. The company's current valuation, with a P/E ratio higher than the industry but lower than peers, is influenced by temporary issues such as slower onboarding for its Inspire V system and Medicare billing updates, which are expected to resolve. Investors are encouraged to consider the company's fundamentals and potential reacceleration of growth in 2026 as these issues clear.
Inspire Medical Systems stock hits 52-week low at 70.41 USD
Inspire Medical Systems stock has fallen to a 52-week low of $70.41, representing a 62.94% decrease over the past year. Despite its strong balance sheet with more cash than debt, the company faces challenges due to changes in Medicare & Medicaid Services (CMS) reimbursement policies for obstructive sleep apnea. Several financial firms have downgraded their outlooks and price targets for Inspire Medical, citing these coding headwinds.
Inspire Medical Systems, Inc. (NYSE:INSP) Stocks Pounded By 28% But Not Lagging Market On Growth Or Pricing
Inspire Medical Systems (NYSE: INSP) shares have dropped 28% in the last month, contributing to a 64% loss over the past year. Despite this, the company's P/E ratio of 44.5x remains high compared to the market average, driven by strong recent earnings growth of 35% and an anticipated 26% annual EPS growth over the next three years, outpacing the broader market forecast. This elevated P/E suggests investors have high expectations for its future performance.
Inspire Medical Systems (INSP) Expected to Beat Earnings Estimates: Should You Buy?
Inspire Medical Systems (INSP) is projected to surpass its earnings estimates for the quarter ended December 2025, with an expected increase in revenues despite a year-over-year decline in EPS. The company's Zacks Earnings ESP of +5.13% combined with a Zacks Rank #3 suggests a high probability of an earnings beat, based on recent analyst revisions. Investors are advised to consider this alongside other factors influencing stock performance ahead of the February 11 earnings release.
Inspire Medical Systems stock hits 52-week low at 70.41 USD
Inspire Medical Systems (INSP) stock has dropped to a 52-week low of $70.41, with the RSI indicating oversold conditions and a 62.94% decline over the past year. Despite a strong balance sheet, the company faces challenges due to a Centers for Medicare & Medicaid Services (CMS) policy update affecting reimbursement for obstructive sleep apnea (OSA), leading to analyst downgrades and reduced price targets from RBC Capital, Jefferies, and Truist Securities. Investors are advised to monitor developments closely as the company's earnings report approaches on February 11th.
Inspire Medical Systems (INSP) Expected to Beat Earnings Estimates: Should You Buy?
Inspire Medical Systems (INSP) is projected to report a year-over-year decline in earnings but higher revenues for the quarter ended December 2025. The company has a Zacks Earnings ESP of +5.13% and a Zacks Rank of #3, suggesting a high probability of beating consensus EPS estimates. Historically, Inspire has consistently surpassed EPS estimates in the past four quarters.
Brown Capital Management LLC Has $20.63 Million Stake in Inspire Medical Systems, Inc. $INSP
Brown Capital Management LLC recently reduced its stake in Inspire Medical Systems, Inc. (NYSE:INSP) by 24.3% in the third quarter, now holding 278,040 shares valued at approximately $20.63 million. This comes as former Director Shawn McCormick also sold 2,000 shares, decreasing his holdings by over 7%. Inspire Medical Systems reported strong quarterly earnings, beating analyst estimates with $0.38 EPS and $224.5 million in revenue, leading to a consensus "Hold" rating among analysts with an average target price of $133.47.
Inspire Lawsuit Alleges Sleep Apnea Implant Problems Concealed
A shareholder lawsuit has been filed against Inspire Medical Systems Inc. and its board of directors, alleging mismanagement of the Inspire V Implantable Pulse Generator (IPG) rollout and concealment of known problems. The lawsuit claims that the board misled shareholders about the company's financial health, leading to artificially inflated stock prices before a significant drop following an August 2025 earnings report. The complaint stems from issues following an Inspire IV IPG recall due to a manufacturing defect and the subsequent problematic introduction of the Inspire V.
Federated Hermes Inc. Sells 124,528 Shares of Inspire Medical Systems, Inc. $INSP
Federated Hermes Inc. significantly reduced its stake in Inspire Medical Systems by selling 124,528 shares, now owning 103,804 shares valued at approximately $7.7 million. Despite this, Inspire Medical Systems reported strong quarterly earnings, surpassing analyst expectations with $0.38 EPS against an anticipated loss. The company's stock, though recently trading down, has seen several analysts adjust their price targets upward, maintaining a consensus "Hold" rating.
Inspire Medical Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Inspire Medical Systems, Inc. - INSP
Kahn Swick & Foti, LLC (KSF) has launched an investigation into the officers and directors of Inspire Medical Systems, Inc. (NYSE: INSP). This follows a class action lawsuit filed after the company reportedly failed to disclose significant issues regarding the launch of its Inspire V device, leading to a substantial cut in its 2025 earnings guidance. KSF's investigation will determine if Inspire's leadership breached fiduciary duties or violated laws.
Kuehn Law Encourages Investors of Inspire Medical Systems, Inc. to Contact Law Firm
Kuehn Law, a shareholder litigation firm, is investigating Inspire Medical Systems, Inc. (NYSE: INSP) for alleged breaches of fiduciary duties by its officers and directors. The investigation stems from allegations that the company misrepresented issues with the Inspire V launch, including a lack of demand, inventory surplus, and incomplete preparation tasks. Investors who purchased INSP prior to August 6, 2024, are encouraged to contact the law firm.
